Hyperthermic intraperitoneal chemotherapy with and without cytoreductive surgery for epithelial ovarian cancer.
Women with epithelial ovarian cancer (EOC) usually present with advanced disease and overall only just over half survive 5 years. Even following a complete response to front-line treatment two-thirds will recur, with a resultant dismal prognosis. We review and discuss the role of surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in EOC and present the results of the ovary consensus panel (OCP) convened for the 5th International Workshop on Peritoneal Surface Malignancy.
Helm
C William
CW
Division of Gynecologic Oncology, James Graham Brown Cancer Center, University of Louisville, Kentucky 40207, USA. cwhelm@uoflobgyn.com
Bristow
Robert E
RE
Kusamura
Shigeki
S
Baratti
Dario
D
Deraco
Marcello
M
D002277:Carcinoma / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000379:methods*; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced; D007263:Infusions, Parenteral; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery